Last10K.com

Enzo Biochem Inc (ENZ) SEC Filing 10-Q Quarterly Report for the period ending Tuesday, October 31, 2023

SEC Filings

ENZ Valuations

Intrinsic Value
Financial Stability
Financial Ratios
Insider Trades
Manager Portfolios
Notifications

ENZ Annual Reports

ENZ Quarterly Reports

ENZ Corporate News

Enzo Biochem Inc

HISTORY TOOLS
CIK: 316253 Ticker: ENZ
Document And Entity Information - shares
3 Months Ended
Oct. 31, 2023
Dec. 08, 2023
Document Information Line Items  
Entity Registrant NameENZO BIOCHEM, INC 
Trading SymbolENZ 
Document Type10-Q 
Current Fiscal Year End Date--07-31 
Entity Common Stock, Shares Outstanding 50,489,771
Amendment Flagfalse 
Entity Central Index Key0000316253 
Entity Current Reporting StatusYes 
Entity Filer CategoryNon-accelerated Filer 
Document Period End DateOct. 31, 2023 
Document Fiscal Year Focus2024 
Document Fiscal Period FocusQ1 
Entity Small Businesstrue 
Entity Emerging Growth Companyfalse 
Entity Shell Companyfalse 
Document Quarterly Reporttrue 
Document Transition Reportfalse 
Entity File Number001-09974 
Entity Incorporation, State or Country CodeNY 
Entity Tax Identification Number13-2866202 
Entity Address, Address Line One81 Executive Blvd 
Entity Address, Address Line TwoSuite 3 Farmingdale 
Entity Address, City or TownNew York 
Entity Address, State or ProvinceNY 
Entity Address, Postal Zip Code11735 
City Area Code(631) 
Local Phone Number755-5500 
Title of 12(b) SecurityCommon stock $0.01 par value 
Security Exchange NameNYSE 
Entity Interactive Data CurrentYes 

View differences made from one quarter to another to evaluate Enzo Biochem Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Enzo Biochem Inc.

Continue

Assess how Enzo Biochem Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Enzo Biochem Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parentheticals)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Income (Loss) (Unaudited)
Consolidated Statements Of Operations (Unaudited)
Consolidated Statements Of Operations (Unaudited) (Parentheticals)
Consolidated Statements Of Stockholders??? Equity (Unaudited)
Accounting Policies, By Policy (Policies)
Accrued Liabilities And Other Current Liabilities
Accrued Liabilities And Other Current Liabilities (Details)
Accrued Liabilities And Other Current Liabilities (Details) - Schedule Of Accrued Liabilities
Accrued Liabilities And Other Current Liabilities (Tables)
Basis Of Presentation
Basis Of Presentation (Details)
Contingencies
Contingencies (Details)
Convertible Debentures And Other Current Debt
Convertible Debentures And Other Current Debt (Details)
Convertible Debentures And Other Current Debt (Details) - Schedule Of Convertible Debentures Measured At Fair Value
Convertible Debentures And Other Current Debt (Tables)
Departure And Appointment Of Certain Officers
Departure And Appointment Of Certain Officers (Details)
Discontinued Operations
Discontinued Operations (Details)
Discontinued Operations (Details) - Schedule Of Condensed Operating Results Of The Discontinued Operations
Discontinued Operations (Details) - Schedule Of Major Classes Of Assets And Liabilities Of The Discontinued Operations
Discontinued Operations (Tables)
Inventories
Inventories (Details) - Schedule Of Inventories, Net
Inventories (Tables)
Leases
Leases (Details)
Leases (Details) - Schedule Of Components Of Lease Cost
Leases (Details) - Schedule Of Lease Agreements Include Rental Payments
Leases (Details) - Schedule Of Lease Liabilities
Leases (Details) - Schedule Of Lease Term And Discount Rate
Leases (Tables)
Long Term Debt
Long Term Debt (Details)
Long Term Debt (Details) - Schedule Of Minimum Future Annual Principal Payments
Long Term Debt (Tables)
Net Income (Loss) Per Share
Net Income (Loss) Per Share (Details)
Revenue Recognition
Revenue Recognition (Details)
Revenue Recognition (Details) - Schedule Of Products Revenue By Geography
Revenue Recognition (Tables)
Segment Reporting
Segment Reporting (Details) - Schedule Of Financial Information Represents The Operating Results Of The Reportable Segments
Segment Reporting (Tables)
Stockholders??? Equity
Stockholders??? Equity (Details)
Stockholders??? Equity (Details) - Schedule Of Share-Based Compensation Expense
Stockholders??? Equity (Details) - Schedule Of Stock Option Activity
Stockholders??? Equity (Details) - Schedule Of Summarizes Restricted Stock Unit (???Rsu???) Activity
Stockholders??? Equity (Tables)
Supplemental Disclosure For Statement Of Cash Flows
Supplemental Disclosure For Statement Of Cash Flows (Details)

Material Contracts, Statements, Certifications & more

Enzo Biochem Inc provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Certification
Exhibit 31.2: Certification
Exhibit 32.1: Certification
Exhibit 32.2: Certification
Ticker: ENZ
CIK: 316253
Form Type: 10-Q Quarterly Report
Accession Number: 0001213900-23-096093
Submitted to the SEC: Fri Dec 15 2023 4:15:29 PM EST
Accepted by the SEC: Fri Dec 15 2023
Period: Tuesday, October 31, 2023
Industry: Medical Laboratories

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/enz/0001213900-23-096093.htm